CosmanF, CrittendenDB, AdachiJD, et al.Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med, 2016; 375:1532–1543.
2.
BarrionuevoP, KapoorE, AsiN, et al.Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: A network meta-analysis. J Clin Endocrinol Metab, 2019; 104:1623–1630.
3.
SaagKG, PetersenJ, BrandiML, et al.Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med, 2017; 377:1417–1427.
4.
Osteoporosis prevention, screening, and diagnosis: ACOG clinical practice guideline no. 1. Obstet Gynecol, 2021; 138:494–506.
5.
The North American Menopause Society (NAMS). Management of osteoporosis in postmenopausal women: The 2021 position statement of The North American Menopause Society. Menopause, 2021; 28:973–997.
6.
CamachoPM, PetakSM, BinkleyN, et al.American Association of Clinical Endocrinologists/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis—2020 update. Endocr Pract, 2020; 26(Suppl. 1):1–46.
7.
SignorelliSS, ScutoS, MarinoE, GiustiM, XourafaA, GaudioA. Anticoagulants and osteoporosis. Int J Mol Sci, 2019; 20:5275.
8.
LutseyPL, NorbyFL, EnsrudKE, et al.Association of anti- coagulant therapy with risk of fracture among patients with atrial fibrillation. JAMA Intern Med, 2020; 180:245–253.
9.
GadsbøllK, StaerkL, FosbølEL, et al.Increased use of oral anti- coagulants in patients with atrial fibrillation: Temporal trends from 2005 to 2015 in Denmark. Eur Heart J, 2017; 38:899–906.
10.
WongCX, GanSW, LeeSW, et al.Atrial fibrillation and risk of hip fracture: A population-based analysis of 113,600 individuals. Int J Cardiol, 2017; 243:229–232.
By the 2019 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc, 2019; 67:674–694.
13.
VestergaardP, Prieto-AlhambraD, JavaidMK, CooperC. Fractures in users of antidepressants and anxiolytics and sedatives: Effects of age and dose. Osteoporos Int, 2013; 24:671–680.
14.
JhaS, WangZ, LaucisN, BhattacharyyaT. Trends in media reports, oral bisphosphonate prescriptions, and hip fractures 1996-2012: An ecological analysis. J Bone Miner Res, 2015; 30:2179–2187.
15.
BlackDM, RosenCJ. Postmenopausal osteoporosis. N Engl J Med, 2016; 374:254–262.
